SV

Street Verdict

Analyst Scorecard

VIJAYA · NSE

Vijaya Diagnostic Centre Limited

₹1,572.3

+4.08% (+₹61.7)

Prev. close

₹1,510.6

Volume

5,38,498

Delivery %

16.6%

As of

20 Nov 2026

Price history

₹1,572.3+₹75 (+5.01%) · 3M
18 Aug 2026 → 20 Nov 2026
1,4001,4501,5001,55018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

1 analyst stance · last 90 days · one per analyst

Trackable

1 · 1 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (1)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Fundamentals

About Vijaya Diagnostic Centre Limited

Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, and molecular diagnostics; radiology services, such as CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, and gastroenterology; and advance radiology service comprising nuclear medicine, positron emission tomography CT, and MRI-3T services. It also provides health checkups and home sample collection services, as well as test services. Vijaya Diagnostic Centre Limited was founded in 1981 and is based in Hyderabad, India.

Details

Sector

Healthcare

Industry

Diagnostics & Research

CEO

Ms. Sura Suprita Reddy

Headquarters

Hyderabad

Employees

2,507

Key stats

Market cap

₹14,673.05 Cr

P/E ratio (TTM)

78.3

Dividend yield

0.14%

EPS (TTM)

₹18.19

Beta (1Y · daily vs NIFTY 50)

0.50

Beta (5Y · monthly vs NIFTY 50)

0.78

Shares float

4.90 Cr

EPS · quarter ended Jun 2026

₹5.15

Financial Performance

01 · Financials

0 Cr250 Cr500 Cr750 Cr1000 Cr₹0%10%20%30%FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

05101520₹FY22FY23FY24FY25FY26

03 · Dividend Profile

01122₹0%25%50%75%100%20 Sept 2213 Sept 2330 Aug 2429 Aug 2516 Sept 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-100%0%100%200%FY22FY23FY24FY25FY26
SalesFixed assetsReceivables (trade + unbilled)Inventory

05 · Capital Structure & Asset Utilization

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹0×0.25×0.5×0.75×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr200 Cr400 Cr600 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
—₹462.37 Cr₹459.22 Cr₹547.81 Cr₹681.39 Cr₹814.20 Cr
EBITDA
—₹216.52 Cr₹196.18 Cr₹239.67 Cr₹290.51 Cr₹357.73 Cr
—₹109.68 Cr₹84.63 Cr₹118.83 Cr₹143.08 Cr₹172.98 Cr
Diluted EPS
—₹10.69₹8.26₹11.59₹13.92₹16.79

Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹541.24 Cr₹713.46 Cr₹853.41 Cr₹982.75 Cr₹1,273.62 Cr₹1,507.05 Cr
₹141.05 Cr₹182.83 Cr₹247.56 Cr₹259.18 Cr₹319.58 Cr₹422.59 Cr
Stockholders' equity
₹359.01 Cr₹468.22 Cr₹544.73 Cr₹657.19 Cr₹795.71 Cr₹957.15 Cr

Fixed assets, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
—₹158.00 Cr₹164.61 Cr₹183.30 Cr₹224.47 Cr₹270.59 Cr
Investing cash flow
—₹-123.06 Cr₹-109.57 Cr₹-142.31 Cr₹-181.87 Cr₹-174.22 Cr
—₹-30.57 Cr₹-41.91 Cr₹-44.55 Cr₹-52.05 Cr₹-69.49 Cr
Capital expenditure
—₹-122.35 Cr₹-124.84 Cr₹-87.96 Cr₹-95.55 Cr₹-182.72 Cr
End cash position
₹6.69 Cr₹11.05 Cr₹24.18 Cr₹22.25 Cr₹12.80 Cr₹39.68 Cr

Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt repaid, Dividends paid, Capital expenditure have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Mar 22(3Q)Jun 22Sep 22–Mar 23(3Q)Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24–Dec 24(2Q)Mar 25Jun 25Sep 25–Dec 25(2Q)Mar 26Jun 26
Promoter54.78%55.04%55.01%54.98%54.90%54.87%54.06%53.93%53.91%53.05%52.63%52.60%52.51%52.47%
Public45.22%44.96%44.99%45.02%45.10%45.13%45.94%46.07%46.09%46.95%47.37%47.40%47.49%47.53%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Vijaya Diagnostic Centre Limited₹14,944.97 Cr₹1,447.179.815.6118.1%0.44+19.5%+41.9%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

VIJAYA

Vijaya Diagnostic Centre falls 2.01% in Thursday's session

Global Banking & Finance Review · 3 days ago

VIJAYA

Vijaya Diagnostic Share Price Rise: Stock Up 5.44% Today

Univest · 7 days ago